Guti--your last statement is the most telling and true:
"The initiation of trials will only raise the price momentarily but results will take the company to a new level."
In short, there is NOTHING in the short-term which will lead to SUSTAINABLE shareholder value. I repeat, nothing.
Meaningful data which will have a LASTING effect on the PPS is now not due out until sometime in 2016, at the earliest.
And by that time one of the biggest run-ups in biotech history may be behind us. The opportunity costs are HUGE holding on to this stock, wouldn't you agree? Or are you not invested elsewhere?
Guti--you don't see those cancer patients either. Being a bit presumptuous with your rhetorical statement? Frankly, I'd be disappointed to hear about something which could potentially be helpful to my condition being delayed, again?
I've read many of your previous informative posts. Surely you've got more than that?
Low volume? I beg to differ Fur. What ticker are you looking at? Scottrade shows volume already at 160% of daily normal. With two hours to go.
Yes. We're frustrated that the most important trial in the company's history has been pushed back (again).
We're also frustrated by the lack of transparency, ambiguity, and clarity in Punit's forward-looking statements. In fact, one could argue that he actually personally lied to some investors about the start of the P2B trial.
Need I say more?
I'm skipping the ticket line and pushing ticketmaster out of the way.
No way this train leaves without me aboard!
I absolutely agree.
Dilution is a fact of life in biotech but, if handled well similar to the management at ADXS and ZIOP, it can actually be viewed as a "good event" and push the stock even higher at the point of dilution.
Jeff said that $150M would be needed for the two P3 trials in 2016.
The partnership for Trimesta is for Trimesta--not the other P3 trials.
Not to worry. We're not there yet. Plenty of other good news (not that this is bad, just a necessary fact of life in biotech.)
Trimesta will be partnered, will need raises (about $150M) for the other two P3 programs for 2016.
Depending on share price, the dilution could be moderate to somewhat substantial in 2016. It all depends on the share price at the time of dilution.
Agreed. It's just it's taking them sooo, sooo long to players in the CAR-T space.
Anyway, is there a ONCS presentation this coming week? If so, when/where? TIA.
Come back and talk to us next week when it's in the 5s.
You've obviously lost a lot of money by following Zack's advice.
Come back an talk to us next week when it's under $4.
Ready to eat crow?
Among other positions, I've actually been trading in and out of ADXS and ATHX. Both are great companies and stocks to hold.
At this time, I do not hold a position in ADXS but do have a position in ATHX. I could be wrong, but I expect ADXS to briefly "cool" its jets while I expect ATHX to break much higher once we get past 3.00.
The bottom line is that there are very few "bad" biotechs these days. Easy money to be made everywhere. Pick your elixir and good luck!